| FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study C Tournigand, T André, E Achille, G Lledo, M Flesh, D Mery-Mignard, ... Journal of Clinical Oncology 22 (2), 229-237, 2004 | 3575 | 2004 |
| Adjuvant trastuzumab in HER2-positive breast cancer D Slamon, W Eiermann, N Robert, T Pienkowski, M Martin, M Press, ... New England journal of medicine 365 (14), 1273-1283, 2011 | 2430 | 2011 |
| Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis C Sotiriou, P Wirapati, S Loi, A Harris, S Fox, J Smeds, H Nordgren, ... Journal of the National Cancer Institute 98 (4), 262-272, 2006 | 1961 | 2006 |
| Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials Early Breast Cancer Trialists' Collaborative Group The Lancet 379 (9814), 432-444, 2012 | 1607 | 2012 |
| Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer M Buyse, S Loi, L Van't Veer, G Viale, M Delorenzi, AM Glas, ... Journal of the National Cancer Institute 98 (17), 1183-1192, 2006 | 1362 | 2006 |
| Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women … P McGale, C Correa, D Cutter, F Duane, M Ewertz, R Gray, G Mannu, ... The Lancet 383 (9935), 2127-35, 2014 | 1195 | 2014 |
| Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases U Pastorino, M Buyse, G Friedel, RJ Ginsberg, P Girard, P Goldstraw, ... The Journal of thoracic and cardiovascular surgery 113 (1), 37-49, 1997 | 1129 | 1997 |
| Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC-> T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab … DJ Slamon Breast Cancer Res Treat 94, S5, 2005 | 1028* | 2005 |
| Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series C Desmedt, F Piette, S Loi, Y Wang, F Lallemand, B Haibe-Kains, G Viale, ... Clinical cancer research 13 (11), 3207-3214, 2007 | 1021 | 2007 |
| OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer—a GERCOR study C Tournigand, A Cervantes, A Figer, G Lledo, M Flesch, M Buyse, ... Journal of clinical oncology 24 (3), 394-400, 2006 | 952 | 2006 |
| Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen M Dowsett, J Cuzick, J Ingle, A Coates, J Forbes, J Bliss, M Buyse, ... Journal of Clinical Oncology 28 (3), 509-518, 2010 | 909 | 2010 |
| The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer MEL Van Der Burg, M Van Lent, M Buyse, A Kobierska, N Colombo, ... New England Journal of Medicine 332 (10), 629-634, 1995 | 881 | 1995 |
| Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade S Loi, B Haibe-Kains, C Desmedt, F Lallemand, AM Tutt, C Gillet, P Ellis, ... Journal of clinical oncology 25 (10), 1239, 2007 | 866 | 2007 |
| Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer Early Breast Cancer Trialists' Collaborative Group New England journal of medicine 319 (26), 1681-1692, 1988 | 849 | 1988 |
| Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes C Desmedt, B Haibe-Kains, P Wirapati, M Buyse, D Larsimont, ... Clinical cancer research 14 (16), 5158-5165, 2008 | 830 | 2008 |
| Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. X Paoletti, K Oba, T Burzykowski, S Michiels, Y Ohashi, JP Pignon, ... Jama 303 (17), 1729-1737, 2010 | 820 | 2010 |
| Preoperative radiotherapy as adjuvant treatment in rectal cancer. Final results of a randomized study of the European Organization for Research and Treatment of Cancer (EORTC). A Gerard, M Buyse, B Nordlinger, J Loygue, F Pène, P Kempf, JF Bosset, ... Annals of surgery 208 (5), 606, 1988 | 808 | 1988 |
| Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials DJ Sargent, HS Wieand, DG Haller, R Gray, JK Benedetti, M Buyse, ... Journal of Clinical Oncology 23 (34), 8664-8670, 2005 | 687 | 2005 |
| Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials D Sargent, A Sobrero, A Grothey, MJ O'Connell, M Buyse, T Andre, ... Journal of Clinical Oncology 27 (6), 872, 2009 | 533 | 2009 |
| The validation of surrogate endpoints in meta-analyses of randomized experiments M Buyse, G Molenberghs, T Burzykowski, D Renard, H Geys Biostatistics 1 (1), 49-67, 2000 | 528 | 2000 |
